Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib

Published:2024-06-10 Issue: Volume: Page:
ISSN:1203-4754
Container-title:Journal of Cutaneous Medicine and Surgery
language:en
Short-container-title:J Cutan Med Surg

Author:

Dababneh Nadine Elias¹,Maazi Mahan²^ORCID,Dababneh Said¹,Popradi Gizelle³,Litvinov Ivan V.⁴^ORCID

Affiliation:

1. Faculty of Medicine, University of Montreal, Montreal, QC, Canada

2. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

3. Division of Hematology, Department of Medicine, McGill University, Montreal, QC, Canada

4. Division of Dermatology, Department of Medicine, McGill University, Montreal, QC, Canada

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/12034754241258364

Reference5 articles.

1. Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil

2. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis

3. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

4. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP